APA (7th ed.) Citation

Mantovani, G., Massa, E., Madeddu, C., Gramignano, G., Astara, G., Lusso, M., . . . Serpe, R. (2005). 51 Pilot study of weekly chemo-hormono-immunotherapy including cisplatin, epirubicin, medroxyprogesterone acetate + rIL-2, followed by docetaxel plus cisplatin in patients with advanced (Stage IIIB-IV) non-small-cell lung cancer (NSCLC). Lung Cancer (01695002), 49, S392. https://doi.org/10.1016/s0169-5002(05)81522-3

Chicago Style (17th ed.) Citation

Mantovani, G., E. Massa, C. Madeddu, G. Gramignano, G. Astara, M. Lusso, V. Cherchi, and R. Serpe. "51 Pilot Study of Weekly Chemo-hormono-immunotherapy Including Cisplatin, Epirubicin, Medroxyprogesterone Acetate + RIL-2, Followed by Docetaxel Plus Cisplatin in Patients with Advanced (Stage IIIB-IV) Non-small-cell Lung Cancer (NSCLC)." Lung Cancer (01695002) 49 (2005): S392. https://doi.org/10.1016/s0169-5002(05)81522-3.

MLA (9th ed.) Citation

Mantovani, G., et al. "51 Pilot Study of Weekly Chemo-hormono-immunotherapy Including Cisplatin, Epirubicin, Medroxyprogesterone Acetate + RIL-2, Followed by Docetaxel Plus Cisplatin in Patients with Advanced (Stage IIIB-IV) Non-small-cell Lung Cancer (NSCLC)." Lung Cancer (01695002), vol. 49, 2005, p. S392, https://doi.org/10.1016/s0169-5002(05)81522-3.